AstraZeneca
The Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. National Institute of Allergy and Infectious Diseases said in a statement.
Trending
Trending
-
We Remember Janey Thompson
-
NC House Rep. Tricia Cotham switches parties and the latest on Donald Trump
-
4-10-24: Tragic News To Announce
-
Bo Thompson Returns to WBT; Tribute To His Daughter Janey
-
4-16-24: An Emotional Day At WBT
-
4-12-24: ABC News Shows True Colors In NC Gov Race
Get Informed!